Australia's most trusted
source of pharma news
Wednesday, 15 October 2025
Posted 14 October 2025 PM
The FDA has approved the subcutaneous version of Keytruda, giving MSD a massive boost as it aims to extend its exclusive rights to the world’s bestselling drug.
Keytruda Qlex has been approved for adult and paediatric solid tumour indications addressed by the original, intravenous version.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.